报价延迟最少15分钟:2026/11/04 16:03 EST
盘后时段
|
||||
|
-- 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
68.63
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.47/3.34
|
|
企业价值
7.81B
|
| 资产负债 |
|
每股账面净值
-2.29
|
| 现金流量 |
|
现金流量率
0.00
|
| 损益表 |
|
收益
806.78M
|
|
每股收益
9.55
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinicallydifferentiated medicines that provide benefits to patients with rare disorders. |
